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Abstract
Plasmacytoid dendritic cells (pDCs) are responsible for the production of type I IFN during viral infection. Viral elimination by
IFN-a-based therapy in more than 50% of patients chronically infected with hepatitis C virus (HCV) suggests a possible
impairment of production of endogenous IFN-a by pDCs in infected individuals. In this study, we investigated the impact of
HCV on pDC function. We show that exposure of pDCs to patient serum- and cell culture-derived HCV resulted in
production of IFN-a by pDCs isolated from some donors, although this production was significantly lower than that induced
by influenza and human herpesvirus type 1 (HHV-1). Using specific inhibitors we demonstrate that endocytosis and
endosomal acidification were required for IFN-a production by pDCs in response to cell culture-derived HCV. HCV and
noninfectious HCV-like particles inhibited pDC-associated production of IFN-a stimulated with Toll-like receptor 9 (TLR9)
agonists (CpG-A or HHV-1) but not that of IFN-a stimulated with TLR7 agonists (resiquimod or influenza virus). The blockade
of TLR9-mediated production of IFN-a, effective only when pDCs were exposed to virus prior to or shortly after CpG-A
stimulation, was already detectable at the IFN-a transcription level 2 h after stimulation with CpG-A and correlated with
down-regulation of the transcription factor IRF7 expression and of TLR9 expression. In conclusion, rapidly and early
occurring particle–host cell protein interaction during particle internalization and endocytosis followed by blockade of TLR9
function could result in less efficient sensing of HCV RNA by TLR7, with impaired production of IFN-a. This finding is
important for our understanding of HCV-DC interaction and immunopathogenesis of HCV infection.
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Introduction
Plasmacytoid dendritic cells (pDCs) are a highly specialized subset
of dendritic cells that function as sentinels for viral infection and are
responsible for production of large amounts of type I IFN during viral
infection [1–3]. pDCs are able to detect genetic material of virus
particles after their degradation in endosomal compartments via
interaction with Toll-like receptors(TLR) [4]. pDCs areable todetect
DNA of inactivated human herpesvirus types 1 (HHV-1) and 2
(HHV-2) via TLR9 (AAQ89443) [5,6], and they are able to detect
single-stranded RNA of inactivated influenza virus and of HIV-1 via
TLR7 (AAQ88659) [7–10]. However, inactivation renders some
single-stranded RNA viruses, like measles [11], respiratory syncytial
virus [11,12], and vesicular stomatitis virus [13], incapable of
inducing potent pDC-associated production of IFN-a.T h er e c o g n i -
tion of such viruses by TLR7 and the production of IFN-a (NP
076918) by pDCs require transport of cytosolic viral replication
intermediates into lysosomes by the process of autophagy [13].
Recent results show that replicating HCV induces an autophagic
response in immortalized human hepatocytes [14].
The eradication of hepatitis C virus (HCV) in more than 50% of
chronically infected patients by treatment with IFN-a in combination
with ribavirin [15,16] suggests that pDCs can play a major role in the
control of HCV infection. Several studies that analyzed the function
of pDCs in chronically infected patients compared with those from
normal subjects reported a markedly reduced IFN-a production after
ex vivo exposure of pDCs to agonists of TLR9 (A/D type CpG
oligonucleotides) and TLR7 (imidazoquinoline components, e.g.,
R848, resiquimod) [17–20]. However, other reports found no
difference between these groups [21,22]. Whereas in these studies,
the pDCs obtained from patients with chronic HCV infection were
exposed to synthetic stimulators of TLR7 or TLR9 in the absence of
HCV, more recent studies investigated the effects of TLR7 or TLR9
ligands on pDCs purified from healthy donors in the presence of cell
culture-prepared HCV (HCVcc) [21,23]. These reports have shown
that exposureof pDCs from healthy donors to HCVcc is not followed
by expression of the HCVcc genome and viral replication, that
HCVcc does not induce pDC-associated production of IFN-a and
cell differentiation [21,23], and that, in addition, HCVcc blocks IFN-
a production mediated via TLR9 [23].
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pDCs to HCV results in production of IFN-a by pDCs isolated from
some donors, although this production is significantly lower than that
induced by influenza and human herpesvirus type 1 (HHV-1).
Production of IFN-a was sensitive to specific inhibitors of endocytosis
and endosomal acidification and was resistant to virus inactivation. In
order to better understand the mechanismof poor induction of IFN-a
by HCVcc-exposed pDCs, we also studied the inhibition of TLR9-
mediated IFN-a production with HCVcc [23] and with HCV-like
particles (HCV-LPs) [24–26]. We conclude that the interaction of the
viral particle with host cell factors during viral internalization and
endocytosis followed by blockage of TLR9 signaling could result in
less efficient sensing of HCV RNA by TLR7, with impaired
production of IFN-a. On the basis of these results we propose a new
mechanism by which HCV can evade recognition by pDCs.
Results
HCV does not induce maturation of purified pDCs
First, we compared the capacity of molecular clone HCVcc
JFH-1 to induce pDC differentiation with the capacities of
resiquimod, influenza virus A/H3N2/Johannesburg, and HHV-
1 KOS (Figure 1). Since TLR7 recognizes and is activated by viral
RNA [27,28], and TLR9 by viral DNA [5,29], we normalized the
quantity of assayed viruses on the basis of the number of virus
genome copies as determined with PCR (not shown). Purified
pDCs from normal healthy donors (Figure 1A) were inoculated
with examined viruses at a multiplicity of 100 genome copies per
cell. All viruses were purified by ultracentrifugation through a
cushion of 20% sucrose to minimize the presence of bystander
activation factors. Analysis of the purity of concentrated stocks of
HCVcc by electron microscopy showed the presence of particles of
60–80 nm in diameter and the absence of detectable amounts of
cellular DNA and RNA (supplementary Figure S1).
One-day-culture ofpDCs inmediumsupplemented with IL-3, an
important factor for pDC survival, resulted in partial pDC
maturation (Figure 1A). pDC viability declined with a half-time of
approximately 1 day (Figure 1B). Flow cytometry analysis of
Annexin V/7ADD-stained cells revealed no increase in the
proportion of apoptotic cells among pDCs inoculated with HCVcc
in comparison with non-stimulated or resiquimod-stimulated pDCs
(Figure 1C–E). Inoculation of pDCs from 10 healthy donors with
HCVcc slightly but significantly down-regulated the expression of
CD80 (ABK41933) and CD86 (CAG46642), whereas the expres-
sion of other assayed surface markers (CD40 (AAL92924), CD83
(CAB63843), and CCR7 (NP 001829)) remained unchanged in
comparison with culture without stimulation (Figure 1F and 1G).
Stimulation of pDCs with TLR7 agonist resiquimod strongly
increased the expression of CD40, CD80, CD83, CD86, and
CCR7. In contrast, stimulation of pDC with TLR9 agonist CpG-A
resulted in significantly increased expression of CCR7 and in only a
moderate increase of the expression of CD80, CD83, and CD40
(Figure 1G). Stimulation with the natural agonist of TLR7 influenza
virus significantly increased the expression of CD80, CD83, and
CCR7, whereas stimulation with the natural agonist of TLR9
HHV-1 significantly increased the expression of CD86, CD83, and
CCR7. Taken together, these findings show that HCV did not
induce, but rather blocked, the maturation of purified pDCs and
had no effect on their apoptosis.
IFN-a production induced by cell culture- and patient-
derived HCV in pDCs
Next, we assayed IFN-a production induced by increasing doses
of infectious HCVcc in purified pDCs from a small panel of
donors (Figure 2). pDCs of 13 donors incubated with HCV JFH
preparations at a dose of 100 HCV RNA copies per target cell
secreted 1.2760.39 (mean6SEM) ng of IFN-a per milliliter. pDCs
of three donors did not produce detectable amounts of IFN-a (the
detection level in ELISA was 10 pg of IFN-a per milliliter),
whereas pDCs from other three donors consistently produced
more than 1 ng of IFN-a per milliliter.
pDCs exposed to 0.5 mM resiquimod, used as a positive control,
produced 9.264.1 ng of IFN-a per milliliter. IFN-a levels
produced by pDCs stimulated with HCVcc did not show any
correlation with levels of IFN-a induced by resiquimod (supple-
mentary Figure S2). The three donors with absent IFN-a
production after stimulation with HCVcc (Figure 2), produced
significant levels of IFN-a (730, 5,352 and 5,827 pg per milliliter)
after stimulation with resiquimod (supplementary Figure S2). In
addition to pDCs, myeloid DCs and macrophages respond to
CpG-DNA and produce small amounts of type-I IFN. In our
experiments, magnetic bead-purified myeloid DCs, the principal
source of possible contamination of pDCs, did not produce any
IFN-a after exposure to HCV. In addition to HCVcc, we
incubated pDCs with a control suspension prepared in the same
manner as the viral stock from cell-free supernatant of Huh7.5
cells transfected with HCV H/SG-neo (L+I) subgenomic replicon
[30]. Because Huh7.5.1 cells were apoptotic at the time of HCVcc
harvest, we rendered the control culture apoptotic by UV-
irradiation [23]. pDCs from four donors exposed to this control
HCVcc virion-free supernatant did not produce significant
quantities of IFN-a (Figure 2) confirming that pDC-associated
production of IFN-a was induced by HCV and not by cellular
components.
To test the biological relevance of results obtained with HCVcc
(genotype 2), we exposed pDCs to similar doses of patient-derived
HCV (genotypes 1a, 1b, 2a, and 3a; Figure 2) compared with
HCVcc. pDC-associated production of IFN-a increased with
increasing levels of HCV genome copies, although at a lower rate
as observed for HCV JFH-1 CAI41940). Taken together, these
data suggest that exposure of pDCs to cell culture- or patient-
derived HCV resulted in production of IFN-a, although it showed
a high degree of variability among pDCs from different donors.
In contrast to influenza virus and HHV-1, HCV is a weak
inducer of pDC-associated production of IFN-a and TNF-a
Next, we compared the capacity of HCV JFH-1 to induce pDC-
associated secretion of IFN-a and TNF-a (CAI41940) with the
capacities of HIV-1 LAI, influenza virus A/H3N2/Johannesburg,
and HHV-1 KOS. pDC-associated production of IFN-a in
different donors (nHCV=13, nHIV-1=8, nHHV-1=8, nFLU=3)
increased with levels of viral genome copies and reached a
maximum at a dose of 100 genome copies per cell for HCVcc,
HIV-1, and influenza virus, whereas the optimum for HHV-1 was
reached at 10 genome-containing virus particles per cell
(Figure 3A). Regression analysis of the linear parts of the activation
curves showed that approximately 0.12 (HHV-1), 0.2 (influenza
virus), 38 (HIV-1), or 51 (HCVcc) genome copies per cell were
necessary for the production of 1 ng of IFN-a per milliliter
(Figure 3B). Comparing the viral genome copy number inducing
the same quantity of IFN-a production, HHV-1 and influenza
virus are 425-fold and 255-fold more potent than HCVcc in
inducing IFN-a production. The difference between the capacity
of HCVcc and HIV-1 to induce pDC-associated production of
IFN-a was not significant (Figure 3A).
Complementing the investigation of IFN-a production, we
studied the stimulatory effect of the four viruses on pDC-associated
TNF-a production (Figure 3C). Similar as seen for IFN-a,
IFN-a in HCV-Exposed pDCs
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dependent production of TNF-a, albeit the level of TNF-a was
markedly lower than the level of TNF-a induced by influenza virus
and HHV-1. Thus, we conclude that HCV, compared to influenza
virus and HHV-1, is a weak inducer of pDC-associated production
of IFN-a and TNF-a.
Activation of pDCs by HCV occurs during viral
endocytosis
To investigate whether endocytosis was required for recognition
of HCV, we tested several inhibitors that block the cellular uptake
of particular structures, including viruses (Table 1). Dimethyl
amiloride, cytochalasin D, and chlorpromazine fully inhibited
IFN-a secretion, suggesting that viral endocytosis is required for
pDCs stimulation. Incubation of pDCs with chloroquine,
quinacrine, and bafilomycin A1 resulted in complete inhibition
of HCVcc-induced IFN-a secretion, showing that acidification/
maturation of the endosomes is necessary for activation of pDCs.
Although less effective than chloroquine, quinacrine or BafA1,
NH4Cl inhibited HCVcc-induced IFN-a secretion in a dose-
dependent manner. Consistent with previous observations that
activation of TLR7 occurs within endosomes, inhibition of IFN-a
production by inhibitors of endocytosis was also observed in
response to resiquimod [31]. In conclusion, our findings suggest
that endocytosis of the HCV particle, with subsequent acidification
of endosomes, is required for pDC activation.
Inactivated HCV stimulates similar levels of pDC-
associated production of IFN-a as replication-competent
infectious virus
The majority of viruses that are presented to TLR by
endocytosis has a similar IFN-a stimulatory potential whether
they are exposed to pDCs in replication-competent or inactivated
form [5–7,9]. Exposure of pDCs to inactivated virus lead to
reduction of IFN-a secretion by only 8% (thermo-inactivated
virus) or 18% (UV-inactivated virus), whereas the infectious titers
(tissue culture infectious dose) of HCVcc determined in Huh7.5.1
producer cells (TCIDHuh7.5.1/ml) dropped 10,000-fold or 1,000-
fold, respectively (Table 2). Similar levels of pDC-associated
production of IFN-a stimulated with inactivated as with
replication-competent infectious virus indicate that, HCV does
not need to be replication-competent to induce IFN-a production
in pDCs and is compatible with a major role of endocytosis in
pDC activation.
Exposure of pDCs to HCVcc prior to or shortly after CpG-
A stimulation blocks TLR9-mediated production of IFN-a
To investigate further the impact of HCV on pDC function, we
studied kinetics of disruption of TLR9-mediated production of
IFN-a. For this reason, we exposed the cells before or after
stimulation with CpG-A to HCVcc, as shown in the chart flow
protocol (Figure 4A). Priming with HCVcc 2 h before CpG-A
stimulation (Figure 4A, line a) reduced the CpG-A-induced IFN-a
levels by .90% (Figure 4B). Less pronounced (69%) inhibition of
TLR9-mediated activation by HCVcc was observed when pDCs
were exposed to HCVcc and CpG-A concomitantly (Figure 4A,
line b and 4B). The inhibitory effect of HCVcc almost disappeared
(12% inhibition) when the virus was added 1 h after CpG-A
(Figure 4A, line c, and 4B). Thus, HCVcc inhibits TLR9-mediated
production of IFN-a only when inoculation with HCVcc precedes
or follows shortly after CpG-A stimulation.
To study events that precede secretion of IFN-a, we examined
the expression of IFN-a, IRF7, TLR7, and TLR9 genes in pDCs
Figure 2. Secretion of IFN-a induced with cell culture-derived
HCVcc and patient-derived HCV in pDCs from different normal
healthy donors. Purified pDCs were inoculated with different
quantities of HCVcc (genotype 2) or patient-derived HCV (genotypes
1a, 1b, 2a, and 3a). Viral genomes were quantified by semiquantitative
RT-PCR. As negative control, a suspension prepared from cell-free
supernatant of Huh7.5 cells transfected with HCV subgenomic (sg)
replicon was used. This negative control suspension was concentrated
and purified in the same manner as the viral suspension used for
exposure of pDCs to 100 genome-containing virus particles per cell.
Resiquimod (R848, 0.5 mM) was used as a positive control. Cell cultures
of pDCs purified from different normal healthy donors adjusted to a
concentration of 10
6 cells/ml in the presence of IL-3 were inoculated
with HCV (quantified by HCV RNA copies) in a total volume of 200 ml.
Secretion of IFN-a in cell-free supernatant was determined by ELISA 1
day post-stimulation. Identical symbols at a given multiplicity of
infection indicate results with pDCs of different donors.
doi:10.1371/journal.pone.0004319.g002
Figure 1. Expression of differentiation markers of pDCs exposed to HCVcc. (A) Cell cultures of pDCs were purified from PBMCs by use of
magnetic beads. The purity of the isolated pDCs was determined from flow cytometry analysis after staining with CD123 and CD11c. Numbers
displayed are percentages of positive cells. Levels of purity from 75% to 95% were repeatedly obtained. Cell cultures of pDCs were adjusted to a
concentration of 10
6 cells/ml in the presence of IL-3, and the expression of the cell surface markers CD80 and CD86 was determined immediately after
cell separation (day 0, gray line) or after 1-day culture (day 1, black line). Isotype control is shown by the gray shadowed area. (B) pDC survival in the
presence of IL-3. (C–E) HCVcc does not induce pDCs apoptosis. (C) Cell cultures of pDCs in the presence of IL-3 were (D) inoculated at a multiplicity of
100 genome-containing virus particles of HCVcc per cell or (E) stimulated with 0.5-mM resiquimod (R848) in a total volume of 200 ml. pDCs were
stained with Annexin V and 7ADD 1 day post-stimulation. (F) pDCs were inoculated at a multiplicity of 100 virus genome copies of HCVcc or influenza
virus A/H3N2/Johannesburg, or they were stimulated with 0.5-mM resiquimod (R848) in a total volume of 200 ml. Expression of CD80, CD86, CD83,
and CCR7 was determined in CD123
+HLA-DR
+ gated live cells 1 day post-stimulation. Black area, virus- or R848-exposed pDCs; gray area, isotype
control. Data are representative of 10 independent experiments with pDCs of different donors that gave comparable results. (G) The mean
fluorescence intensity (MFI) rate corresponds to the MFI of a sample divided by that of non-stimulated cells. The data show means and SEM of 10
independent experiments with pDCs of different donors stimulated with HCVcc, influenza virus A/H3N2/Johannesburg, R848, HHV-1 KOS, or CpG-A.
+, significant induction of the respective cell surface marker as compared with the corresponding non-stimulated control; *, significant suppression of
the respective cell surface marker as compared with the corresponding non-stimulated control (non-parametric Mann-Whitney test).
doi:10.1371/journal.pone.0004319.g001
IFN-a in HCV-Exposed pDCs
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both HCV JFH-1 and CpG-A (Figure 4A, line a, and 4C). In four
experiments with pDCs purified from three donors, CpG up-
regulated IFN-a expression in pDCs from 2,100- to 12,000-fold by
4 h, while simultaneous stimulation with HCVcc reduced the up-
regulation of IFN-a expression by 18 to 76 times. Relative IFN-a
expression then dropped down approximatively 10 times after
16 h of CpG stimulation, in comparison with the level of
expression after 4 h. In pDCs purified from different donors
HCV up-regulated IFN-a expression from 1 to 44 times.
Since the ability of CpG-A to induce IFN-a was severely
impaired in the presence of HCVcc, we examined TLR7 and
TLR9 expression in CpG-A-stimulated cells. Incubation of pDCs
with CpG-A resulted in up-regulation of TLR7 expression in
pDCs after 2 h and later. By contrast, expression of TLR9 was
down-regulated. Priming of pDCs with HCVcc slowed down the
TLR7 up- and TLR9 down-regulation by approximately 50%.
Because triggering of TLR9 and/or TLR7 is known to activate the
IRF-7-mediated pathway, we also examined the expression of this
molecule, which is responsible for the transcription of IFN-a, and
which is constitutively present in pDCs (Figure 4C). Modest up-
regulation (1.6 times) of IRF-7 expression in CpG-A-stimulated
pDCs was reduced by approximatively 50% in HCVcc-primed
cells. Taken together, blockade of stimulation via TLR9 occurs
early after exposure of pDCs to HCV and correlates with down-
regulation of IRF7.
HCVcc and HCV-LPs but not HCV core or envelope
glycoprotein E2 inhibit pDC-associated production of
IFN-a stimulated via TLR9
We assayed whether non-infectious HCV-LPs, HCV core
(BAA01000), and envelope glycoprotein E2 disrupt TLR9-
mediated production of IFN-a, in addition to the reported effect
of HCVcc [23]). pDCs primed with HCVcc for 2 h and
subsequently stimulated with CpG-A produced IFN-a at
11.265.4% of the levels produced by pDCs stimulated only with
CpG-A (Figure 5A). This reduction was highly significant relative
to that in CpG-A-treated cells from 10 healthy donors in 14
experiments (p=0.0002) and relative to control supernatants from
Huh7.5 cells transfected with subgenomic replicon and rendered
apoptotic by UV irradiation (p=0.01). Inhibition of TLR9-
mediated production of IFN-a was HCVcc dose-dependent and
dropped to negligible level in pDCs exposed in average to one
HCVcc RNA molecule per cell.
To test the biological relevance of results obtained with cell
culture-derived HCV, we determined the level of inhibition of
TLR9-mediated activation by patient serum-derived HCV
(Figure 5A). pDCs primed for 2 h with HCV from patients
(n=5) and subsequently stimulated with CpG-A produced IFN-a
at 19.365.9% of the levels produced by pDCs stimulated only
with CpG-A, whereas pDCs primed with sediments prepared by
ultracentrifugation through a cushion of 20% sucrose of sera
obtained from four HCV-negative individuals produced IFN-a at
58.3611.6% of the levels produced by pDCs stimulated only with
CpG-A (Figure 5A). The difference between inhibition of TLR9-
mediated activation by HCV from patients’ serum and healthy
controls was significant (p=0.032).
In addition to CpG-A, we tested the effect of HCV on the
stimulation of pDCs by HHV-1, a naturally occurring TLR9
agonist (Figure 5A). Exposure of pDCs to HCV followed by
inoculation with HHV-1 reduced IFN-a secretion by .60% in
comparison with pDC culture exposed only to HHV-1. Control
HCV virion-free supernatant from Huh7.5 cells transfected with
HCV subgenomic replicons did not significantly block HHV-1-
induced IFN-a secretion.
To determine whether replication-competent HCV is required
for the inhibitory effect, pDCs were exposed to heat-inactivated or
UV-inactivated virus or to HCV-LPs in the presence of CpG-A.
Heat-inactivated as well as UV-inactivated HCVcc suppressed
CpG-A-induced IFN-a secretion by .80%, as did the replication-
competent virus (Figure 5A).
Table 1. Sensitivity of IFN-a production to inhibitors of
endocytosis.
Endocytosis inhibitor IFN-a production, %*
HCVcc 0.5 mM resiquimod
Dimethyl amiloride (50 mM) ,5% ,5%
Cytochalasin D (10 mM) ,5% ,5%
Chlorpromazine (6.25 mM) ,5% ,5%
Chloroquine (5 mM) ,5% ,5%
Quinacrine (5 mM) ,5% ,5%
NH4Cl (1 mM) 80% 45%
NH4Cl (10 mM) ,5% ,5%
Bafilomycin A1 (50 nM) ,5% ,5%
*Percentage of mock-treated control. pDCs (300,000 cells) were exposed to
3610
7 HCVcc RNA copies in a final volume 300 ml for 16 h.
doi:10.1371/journal.pone.0004319.t001
Table 2. Exposure of pDCs to heat-inactivated and UV-
inactivated virus stimulates production of IFN-a
*.
TCIDHuh7.5.1/ml TCIDHuh7.5.1/ml IFN-a IFN-a
% pg/ml %
HCV 10
5 100 120638 100
HCV, 30 min 56uC ,10
1 ,0.01 111625 92
HCV 10
5 100 175642 100
HCV, UV (0.2 J/cm
2)1 0
2 0.1 142640 81
*10
8 HCVcc RNA copies and 10
6 pDCs per milliliter.
doi:10.1371/journal.pone.0004319.t002
Figure 3. Secretion of IFN-a and TNF-a by purified pDCs inoculated with HCVcc, HIV-1 NL4.3, influenza virus A/H3N2/
Johannesburg, or HHV-1 KOS, or stimulated with resiquimod or CpG-A. Cell cultures of pDCs purified from PBMCs of different healthy
donors (nHCV=13, nHIV-1=8,nHHV-1=8,nFLU=3) adjusted to a concentration of 10
6 cells/ml in the presence of IL-3 were inoculated with increasing
doses of examined viruses in a total volume of 200 ml. The quantity of virus particles was determined by means of semiquantitative RT-PCR for HCV,
HIV, and influenza virus, and by means of semiquantitative PCR for HHV-1. (A) Secretion of IFN-a. For HCV, the same data as in Figure 2 are shown. (B)
Capacity of HCV, HHV-1, or influenza virus to stimulate IFN-a production as a function of the number of virus genome copies per cell. Analysis of
linear parts of the activation curves shown in panel A was performed by means of linear regression. (C) Secretion of TNF-a. Secretion of IFN-a and
TNF-a in cell-free supernatant was determined by means of ELISA analysis 1 day post-stimulation. ***, statistically significant differences (p,0.0001,
Mann-Whitney test); R848, resiquimod.
doi:10.1371/journal.pone.0004319.g003
IFN-a in HCV-Exposed pDCs
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we primed pDCs with non infectious HCV-LPs instead of HCV
(Figure 5A). HCV-LPs are generated by self assembly of the HCV
structural proteins in insect cells and have been shown to have
similar biophysical, antigenic and immunogenic properties as
HCV particles [25,32–34]. Due to the lack of a functional genome
and the nonstructural proteins, HCV-LPs are noninfectious. Since
DCs efficiently take up, process and present HCV-LPs to HCV-
specific CD4
+ and CD8
+ T cells, the interaction of HCV-LPs with
DCs has allowed to identify mechanisms of HCV uptake and
cross-presentation by human dendritic cells [25,26]. Priming with
HCV-LPs reduced the CpG-A–induced IFN-a levels by .75%
compared to priming with control preparations. The absent
inhibition of CpG-A–induced IFN-a production by control cell
preparations produced from insect cells infected with a control
baculovirus ruled out that contaminating cellular proteins of virus
preparations were responsible for blocking TLR9 function. In
contrast to HCVcc and HCV-LPs, HCV E2 (AAB30986) or core
protein did not inhibit TLR9-mediated activation of pDCs. In
conclusion, these data indicate that HCV virions or virus-like
particles, but not the soluble forms of core and envelope
glycoprotein E2 suppress stimulation via TLR9.
In addition to production of large amounts of IFN-a, TLR
activation of pDCs can induce the production of proinflammatory
cytokines such as TNF-a and IL-6. Similar to the marked
inhibition of TLR9-mediated induction of IFN-a, exposure of
pDCs with cell culture-derived HCV resulted in a more than 80%
inhibition of CpG-A-induced TNF-a production (Figure 5B). A
less pronounced effect of HCV on TNF-a production (blockade
.40%) was observed when the cells were stimulated by HHV-1, a
naturally occurring TLR9 agonist, instead of CpG-A (Figure 5B).
In marked contrast, HCV exerted no discernible effect on pDC
response to TLR7-mediated induction of IFN-a secretion
(Figure 5C). Neither HCV (12 experiments with pDCs from nine
healthy donors), nor heat-inactivated HCV, nor HCV E2, nor
patient-derived HCV, nor HCV-LPs, nor cell-free supernatant
from Huh7.5 cells transfected with subgenomic replicon sup-
pressed pDC-associated secretion of IFN-a induced with a
synthetic ligand (resiquimod) or with a natural agonist (influenza
virus) (Figure 5C). Thus, the HCV-induced suppression of TLR9-
mediated IFN-a secretion is not due to a generalized effect of
HCV on TLR signaling in pDCs.
Discussion
In the present study, we demonstrate that HCV, in contrast to
influenza virus or HHV-1, is a weak inducer of IFN-a in purified
pDCs from healthy donors, and it does not induce pDC
maturation. As in our study, no maturation was detected in pDCs
from HCV-infected individuals [21,23]. Sensitivity of IFN-a
production to inhibitors of endocytosis (dimethyl amiloride,
cytochalasin D, and chlorpromazine) suggests that HCV enters
pDCs by the endocytosis pathway. Because TLR7- and TLR9-
mediated signaling depends on acidification and maturation of
endosomes [35–38], the endocytosis inhibitors that prevent
endosomal acidification (chloroquine, quinarcine, bafilomycin A1
and NH4Cl) block IFN-a production but are not specific for
endocytosis of HCV. A similar production of IFN-a induced by
Figure 4. Kinetics of disruption of CpG-A-mediated stimulation of pDCs with HCVcc. (A) Flow chart protocol showing inoculation with
HCV (solid arrows), treatment with CpG-A (dashed arrows), and IFN-a assay determined by ELISA. (B) Percentage of IFN-a secreted by pDCs that were
stimulated with CpG-A and HCV relative to IFN-a secretion by pDCs stimulated only with CpG-A. Purified pDCs were inoculated with 100 HCVcc RNA
copies per cell. (C) Effect of HCVcc on the expression of IFN-a, IRF-7, TLR7 and TLR9 mRNA. pDCs were primed with HCVcc and stimulated with CpG-A
as shown in panel A, line a. The gene expression levels were determined with real-time PCR were normalized to GAPDH expression. Data are
presented as fold induction over medium control at time zero (given the value of 1.0) and are from one of three representative experiments.
doi:10.1371/journal.pone.0004319.g004
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UV-irradiation suggests that an HCV replication-competent
phenotype is not required for pDC-associated production of
IFN-a and is compatible with HCV recognition in pDCs by
endocytosis mechanism. In hepatocytes, HCV enters target cells
by clathrin-mediated endocytosis, followed by a fusion step from
within an early acidic endosomal compartment [39,40]. In
contrast to hepatocytes, endocytosis of HCV in pDCs is not
followed by expression of HCV genome and viral replication [21].
Differences in the number of assayed donors, in the viral strain,
and virus titer could be the reason why no production of IFN-a
was detected in in vitro HCV-exposed in some other studies
[21,23]. Limited production of IFN-a as well as the absence of
pDC differentiation may contribute to the reduced innate and
adaptive immune responses against HCV observed in the course
of chronic infection [41–45]. Both HCV and HIV-1, which are
related to chronic diseases accompanied by sustained plasma
viremia, are weak inducers of IFN-a and TNF-a. In contrast,
influenza virus and HHV-1, the potent inducers of IFN-a and
TNF-a are related to diseases with transient viremia.
In order to better understand the low production of IFN-a by
HCV-exposed pDCs, we studied HCV-induced blockage of
TLR9-mediated production of IFN-a. We demonstrate that in
addition to HCVcc [23], HCV-LPs also block TLR9-mediated
production of IFN-a. It has recently been demonstrated that pDCs
cultured in the presence of IL3 bind HCV-LPs [25]. Blockage of
CpG-A-induced production of IFN-a by HCV-LPs unequivocally
shows that replication-competent phenotype and expression of the
nonstructural proteins of HCV are not required for the inhibition.
Furthermore, these data demonstrate that an interaction of the
viral particle with host cell factors during viral uptake and
endocytosis is involved in inhibitory mechanism. Since recombi-
nant soluble core and E2 proteins did not inhibit CpG-A induced
production of IFN-a, it is likely that the presence of conformation-
dependent epitopes within the HCV particle are required for
HCV sensing by pDCs. It is possible that soluble forms of core and
E2 proteins could be found in different compartments to HCV
particles and could therefore be unavailable for TLR9-mediated
inhibition of IFN-a secretion. Therefore, core and E2 proteins
cannot be excluded from inhibitory effects. Alternatively, the E1
protein (which was not tested in this study) could play a role in
mediating the inhibition to CpG-A induced production of IFN-a.
A recent report by Amjad et al. [46] showed that non-structural
proteins of HCV (namely NS3 and NS5) inhibit TLR9-induced
IFN-a secretion. Because HCV particles do not contain non-
structural proteins and because HCV does not express its genome
in pDCs [21], it is difficult to interpret these results in the context
of interaction of NS3 and NS5 with circulating pDCs studied in
our work. However, this inhibition could be more important in
infected liver, where the interaction of pDCs with NS3 and NS5
Figure 5. Effect of HCV, HCV-LPs, HCV core, and envelope
glycoprotein E2 on the secretion of IFN-a from pDCs stimulat-
ed with TLR7 or TLR9 agonists. (A) Purified pDCs were exposed to
100, 10, or 1 HCVcc RNA copies per cell or to patient sera-derived HCV.
Alternatively, pDCs were primed with the same quantity of virus
inactivated with heat-treatment at 56uC for 30 min (HCVcc, 56uC) or
with UV-treatment at 0.2 J/cm
2 (HCVcc, UV), or exposed to noninfec-
tious insect cell-derived HCV-LPs (0.1 mg E2/ml corresponding to
approximately 5,000 particles per cell) or to control (ctrl) cell
preparations (1 mg/ml). pDC were also incubated with HCV core or
envelope glycoprotein E2 (10 mg/ml), or with an equivalent volume of
control supernatant collected 16 h after UV irradiation of Huh7.5 cells
transfected with HCV subgenomic replicon at 30 mJ/cm
2 prepared in
the same way as the viral stock (Sg-replicon, UV). pDCs were also
primed with HCV virus particles (100 HCV genomes per cell) prepared
from five different sera of chronically infected patients (HCV
+ serum) or
from equivalent volumes of four different sera of healthy individuals
(HCV
2 serum). Two hours later, primed or mock-primed pDCs were
stimulated (A) with TLR9-agonists, with CpG-A (2.5 mg/ml), or with HHV-
1 KOS (multiplicity of infection=100), or (C) with TLR7-agonists, with
resiquimod (R848, 0.5-mM), or with influenza virus A/H3N2/Johannes-
burg (multiplicity of infection=100). Secretion of IFN-a (A, C) or TNF-a
(B) in cell-free supernatant of pDCs was determined by means of ELISA
analysis 1 day post-stimulation. The results are expressed as percent-
ages of IFN-a production from pDCs that were first primed as specified
above and then further treated with the respective TLR agonist relative
to IFN-a production from pDCs stimulated only with the respective TLR
agonist. pW, Wilcoxon matched pairs test used to compare differences
between the distributions of IFN-a production in primed and non-
primed pDC-cultures; pM-W, Mann-Whitney two-tailed non-parametric
test used to compare differences between the distributions of IFN-a
production in HCV-exposed and Sg-replicon-exposed pDC cultures, or
in HCV
+serum-exposed and HCV
2 serum-exposed pDC cultures.
doi:10.1371/journal.pone.0004319.g005
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underway to fine map the factors within the viral particle and to
identify the host cell proteins mediating this effect.
Several mechanisms could be responsible for the weak
responsiveness of pDCs to HCV on one hand, and the blockage
of TLR9-mediated production of IFN-a on the other. It is
conceivable that the poor secretion of IFN-a by pDCs could be
related to HCV cross-linkage of a variety of cell surface receptors
that down–regulate IFN-a production, such as BDCA-2
(Q8WTT0) [47,48], DCIR (NP 919429) [49], ILT7-FceRI
gamma (AAD02203) [50], and FceRI (CAA46955) [51]. Among
them, ligation of DCIR is followed by co-localization of DCIR and
CpG-A in endosomes, which results in a specific TLR9- but not
TLR7-mediated inhibition of IFN-a and TNF-a [49]. Inhibition
of both IFN-a and TNF-a was seen also in our experiments with
HCVcc (Fig. 5A,B). It is conceivable that HCVcc and HCV-LPs
are, after ligation of a cell surface receptor, transported to the
vicinity of TLR9 and that they use (as a ‘‘wrong cargo’’) the
mechanism of spatiotemporal regulation of IFN-a induction [52]
to escape from recognition by TLR7, the presumed natural
receptor for HCV [53].
The blockade of TLR9-mediated production of IFN-a,e f f e c t i v e
only when pDCs were exposed to virus prior to or shortly after CpG-
A stimulation, was already detectable at the IFN-a transcription level
2 h after stimulation with CpG-A and correlated with down-
regulation of IRF7 expression. Whereas TLR7 and TLR9 signal
transduction pathways downstream of Toll-IL-1R overlap, the
regulation of the gene expression of TLR7 and that of TLR9 are
substantially different. Up-regulation of TLR7 expression and down-
regulation of TLR9 expression inCpG-A-stimulated pDCs, observed
also in previous studies [54,55], had been reduced to approximately
50% after pre-stimulation with HCV JFH-1. Constitutively lower
expression levels of TLR9 compared to TLR7 in normal pDCs
[56,57] could enhance the former mechanisms and make TLR9
more vulnerable to inhibitory effects. Because pDCs stimulated
through TLR9 are refractive to re-stimulation [58], we suppose that
host cell proteins potentially involved in both traffic of the viral
particle and inhibition of TLR signaling, make pDCs non-responsive
to the second signal given by CpG-A. Taken together, rapidly and
early occurring HCV particle-host cell protein interaction during
particle internalization and endocytosis is followed by blockade of
TLR9 by cellular host protein with impaired production of IFN-a.
Supposed sequestration of viral particle in the proximity of TLR9
could result in less efficient sensing of HCV RNA by distal TLR7,
without affecting TLR7 function, as shown by responses to
resiquimod. Triggering the endocytosis of host molecule(s) that
inhibit TLR9 signaling and transport virus particles toward TLR9,
out of contact with TLR7, could represent a new mechanism by
which HCV evades the immune system.
In spite of our efforts to minimize the presence of bystander
activation factors in viral stocks, such as preparations of HCV
JFH-1, it is possible that the virus preparations were contaminated
with membranous vesicles and other RNA- and DNA-containing
cellular components that were co-purified with the virus. This
cellular material could theoretically participate, in addition to
HCV, in the stimulation of pDC-associated production of IFN-a
and in the suppression of CpG-A-induced IFN-a secretion from
pDCs exposed to HCV. To address this issue, we stimulated pDCs
with a suspension prepared from cell-free supernatant of apoptotic
Huh7.5 cells transfected with HCV subgenomic replicon. This
control HCV-free supernatant did not induce pDC-associated
production of IFN-a and did not block CpG-A-induced IFN-a
secretion. Furthermore, similar levels of IFN-a secreted from
pDCs stimulated by HCV virions purified from different biological
materials—recombinant cell culture-derived as well as patient-
derived HCV—further confirm the induction of pDC-associated
IFN-a by HCV and not by cellular components. Side-by-side
control experiments using preparations of cell lysates containing all
proteins or cellular factors potentially contaminating particle
preparations confirm that HCV-LPs, and not contaminating
material, blocked CpG-mediated activation of pDCs.
Variability of the levels of IFN-a produced by the HCV-exposed
pDCs from different donors could reflect polymorphism of the
HCV-induced inhibitory mechanisms and could result in different
outcomes of HCV infection (spontaneous resolution versus
chronicity). Optimal viral concentration that blocked CpG-A-
mediated production of IFN-a by isolated pDCs corresponded to
10
8 HCVccRNAmolecules (andapproximatelyto5610
9 HCV-LP
particles) per milliliter. Only marginal inhibition was observed at
100 times lower HCVcc RNA concentration. Given that most
chronically infected patients have levels of HCV RNA between 10
5
and 10
7 copies per milliliter, the virus concentration necessary for in
vitro inhibition of TLR9-mediated production of IFN-a is
compatible with the block of IFN-a in approximately 0.1 to 10%
of circulating pDCs, and with the observation that individuals
chronically infected with HCV are not immunocompromised.
Similar to our results obtained for HCV, several other viruses
have been shown to block stimulation via TLR9. As recently
shown by Fauci and colleagues [59], HIV-1 gp120 (AAC37925) - a
BDCA-2 [59] and DCIR ligand [60] - inhibits TLR9-mediated
activation and IFN-a secretion, but not TLR7-mediated activation
and IFN-a secretion in pDCs. Hepatitis B virions also selectively
inhibit TLR9-mediated activation and IFN-a secretion (I. E.
Vincent, C. Trepo, personal communication [61]), showing that
two hepatitis viruses impair the same pDC function.
Obvious caveats must be considered in transposition of in vitro
results based on analysis of isolated pDCs exposed to HCVcc in an
‘‘acute setting’’ [23], to ex vivo experiments based of analysis of
complex interactions of pDCs with monocytes/macrophages
[19,62] and NK cells [63] in ‘‘chronical setting’’, and to
pathogenesis of HCV in infected individuals. A better under-
standing of the stimulation of TLR7 and TLR9 with their
synthetic ligands in the presence of HCV may identify new
approaches for the development of antiviral strategies based on
TLR agonists. Recent clinical studies have shown that adminis-
tration of TLR7 agonists resiquimod [64] and isatoribine [65], as
well as of TLR9 agonist CpG-A [66] results in reduction of plasma
virus concentration in patients with chronic HCV infection.
Materials and Methods
pDC isolation and culture
We prepared peripheral blood mononuclear cells (PBMCs)
using density gradient centrifugation on Lymphoprep (AbCys
S.A., Paris, France). pDCs were purified directly from PBMCs by
use of magnetic bead isolation kits followed by separation on
AutoMacs (Miltenyi Biotech). The BDCA-4 diamond isolation kit
(Miltenyi Biotech) was used and yielded levels of purity from 75%
to 95%, with a contamination of less than 5% myeloid dendritic
cells. In some experiments in which we wanted to achieve the
highest purity of pDCs, we pre-enriched dendritic cells from
PBMCs to 50–70% purity by means of magnetic bead depletion of
erythrocytes, monocytes, and T-, B-, and NK-cells using MAbs
against CD3-CD19-CD56-CD14-CD34-CD16-CD66b and gly-
cophorin A (Human Dendritic Enrichment Kit: Stem Cell
Technologies, Inc., Grenoble, France). We then separated pDCs
from the enriched population by means of fluorescence-activated
cell sorting (FACS-ARIA, Becton-Dickinson Bioscience, Erembo-
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CD14-CD216-CD19-CD20-CD56), PE-Cy5-conjugated CD123
MAb, Pe-Cy7-conjugated HLA-DR MAb, and APC-conjugated
CD11C MAb. All conjugated MAbs were purchased from Becton-
Dickinson. pDCs were gated as lin-FITC negative, HLA-DR-Pe-
Cy7 positive, CD123-PE-Cy5 positive, and CD11c-APC negative.
Levels of purity from 95% to 99% were repeatedly obtained.
Isolated pDCs were cultivated in RPMI 1640 supplemented with
10% fetal calf serum and antibiotics. To optimize viability,
recombinant IL3 (R&D Systems Europe, Ltd, Abingdon, UK) was
added to a final concentration of 10 ng/ml.
In vitro pDC stimulation
Purified pDCs were kept at the concentration of 10
6 cells/ml in
the medium containing IL3, for 2–3 h, aliquoted in 100-ml
quantities in 96-well round-bottom culture plates, and stimulated
in a final volume of 200 ml with medium alone, with CpG-A
(ODN 2216 Invivogen), with CpG-A control, with resiquimod (a
generous gift of 3M Pharmaceuticals, St. Paul, MN, USA), or with
assayed viruses. Time curves performed revealed that an overnight
incubation was optimal for quantifying the dendritic cell-
associated cytokine production.
Production and purification of cell culture-derived HCV
(JFH1)
The HCV genotype 2A clone JFH-1, derived from a Japanese
patient with fulminant hepatitis [67,68], was prepared as previously
described in detail [67]. Briefly, plasmid pJFH1 (kindly provided by
T. Wakita, Tokyo Metropolitan Institute for Neuroscience, Tokyo,
Japan) was used as a template for in vitro transcription with the
MEGAscript
TM T7 kit (Ambion, Austin, TX, USA). We then
electroporated HCV RNA (10 mg) in 5610
6 Huh7.5.1 cells (kindly
provided by S. L. Wieland and F. V. Chisari, The Scripps Research
Institute, La Jolla, CA) at 270 V and 960 mF using a Bio-Rad Gene
Pulser system. Transfected cells were then transferred to complete
DMEM supplemented with 10% fetal calf serum and passaged
every 3–5 days. The infectious endpoint titers of HCVcc were
determined from production of cytopathic effect after infection of
Huh7.5.1 cells with tenfold dilutions of virus-containing cell-free
supernatant in duplicate. We prepared virus stocks by infecting 10
7
Huh7.5.1cellswith10
3 TCIDHuh7.5.1ofJFH-1virusharvested from
an RNA transfection experiment. Maximum titers of up to 10
5
TCID Huh7.5.1/ml in the supernatant were reached between 14 and
20 days post-infection. The titers of HCVcc genome-containing
virus particles determined routinely with semiquantitative RT-PCR
were 100 to 1,000 times higher than infectious titers. After 1,000-
fold concentration by ultracentrifugation, the infectious titers
typically increased 20-fold, whereas the titers of HCV genome-
containing virus particles increased approximately 200-fold.
As a control, we used cell-free supernatant from Huh7.5 cells
transfected with H/SG-neo (L+I) subgenomic replicon [30] (kindly
provided by C. M. Rice, The Rockefeller University, New York, NY)
UV-irradiated at 30 mJ/cm
2 in a UV Stratalinker 1800 equipped
with an integral UV photometer (Stratagene, La Jolla, CA).
Patient-derived HCV
Each patient provided informed consent to participation in this
study in accordance with institutional and regulatory guidelines.
We quantified and genotyped HCV RNA from each serum
sample using a branched DNA assay (Quantiplex HCV RNA 2.0
assay; Chiron Diagnostics) and a line probe assay (Inno-LiPA
HCVII; Innogenetics), respectively. All serum samples were stored
at 280uC until use.
Production and purification of HCV-LPs
HCV-LPs derived from the cDNA of the infectious clone H77
were expressed and purified as described previously [24] [26].
Control preparations were derived from insect cells infected with a
recombinant baculovirus containing the cDNA for b-glucuroni-
dase (GUS) [24,26]. The quantity of HCV-LPs was determined by
analysis of the HCV-LP E2 concentration using an E2-specific
ELISA [69] [26]. An HCV-LP E2 concentration of 0.1 mg/ml
corresponded to approximately 5610
8 virus particles/100 mlo r
about 5,000 viral particles per cell (estimation of particles
according to [32]).
HIV-1, HHV-1, and influenza virus stocks
HIV-1 LAI virus stocks were prepared in PHA-activated
PBMCs cultivated in RPMI 1640 medium supplemented with
200-U/ml recombinant IL-2 (Chiron), 15% fetal calf serum, and
antibiotics as previously described in detail [70]. Stocks of HHV-1,
strain KOS (ATCC, VR-1493), were produced in Vero cells.
Influenza virus A/H3N2/Johannesburg/34/99 (kindly provided
by M. Mehtali and A. Leon, Vivalis SA, Nantes, France) was
produced in avian cell line EB14 clone 074.
Virus concentration
Pooled supernatants from infected cells were centrifuged at
4,000 rpm for 7 min to remove cellular debris, passed through a
MillexH-HV PVDF 0.45-mm filter (Millipore, Bedford, MA), and
then pelleted at 40,000 rpm in a Beckman 45Ti rotor for 1 h. The
virus pellets were resuspended in RPMI 1640 medium and
centrifuged through a cushion of 20% sucrose at 35,000 rpm in a
Beckman SW41 rotor for 2 h. The ultracentrifuged virus was
resuspended in RPMI 1640 medium and centrifuged again at
35,000 rpm in the Beckman SW41 rotor for 2 h to remove the rest
of the sucrose and to obtain a 1,000-fold concentrated virus
suspension. HCV viral particles from the serum samples of
infected patients and supernatants from Huh7.5 cells transfected
with H/SG-neo (L+I) subgenomic replicon were ultracentrifuged
and purified under the same conditions.
HCVcc virus inactivation
Concentrated virus at 10
9 RNA copies/ml was inactivated by
heat treatment for 30 min at 56uC or by exposure to 0.2-J/cm
2
UV with a UV Stratalinker 1800 equipped with an integral UV
photometer (Stratagene, La Jolla, CA). pDCs were inoculated with
virus in a quantity equivalent to 100 genome-containing virus
particles per cell. This quantity of genome equivalents corre-
sponded to an HCV infectious dose of 0.01–0.1 tissue culture
infectious doses per Huh7.5.1 indicator cell.
Quantitation of viral genome copies
Using the QIAamp viral RNA kit (Qiagen, Hilden, Germany),
we isolated RNA from virions present in the ultracentrifuged virus.
We determined endpoint dilution titers of viral genome copies with
semiquantitative RT-PCR using the Superscript One Step RT-
PCR system (Invitrogen, Cergy Pontoise, France). The HCV 59-
untranslated region was amplified by means of nested PCR as
described previously [71]. Alternatively, HCV RNA was quantified
on the basis of a real-time reverse transcription polymerase chain
reaction using the primer RTU1 [71] for cDNA synthesis, primer
pair UTR2 and RTU2 [71] for PCR amplification, and HCV JFH-
1 RNA prepared in vitro by means of T7 polymerase as a standard.
For PCR amplification of the HIV LTR, we used the following
primer pairs: 59-CTGTGGATCTACCACACACAAGGCTAC
(sense; L2) and 59- GCTGCTTATATGTAGCATCTGAGGGC
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TACACACCAG (sense; L4) and 59-CCAGCGGAAAGT-
CCCTTGTAG (antisense; L5) for the nested round.
Influenza virus Johannesburg H3N3 was amplified as described
previously [72]. DNA from purified virions of HHV-1 (strain
KOS) was extracted with SDS and proteinase K, purified further
with phenol/chloroform, and amplified by means of PCR as
described in [73]. Reaction mixtures were amplified in a Biometra
T3 Thermocycler (Biometra, Goettingen, Germany) for 40 cycles
at 95uC for 1 min, 60uC for 1 min, and 72uC for 1 min.
Gene expression assay and analysis
We extracted total RNA using the Qiagen RNeasy micro kit
(Qiagen, Courtaboef, France) and converted it to cDNA using
random hexamers (High Capacity cDNA RT kit, Applied
Biosystems, Courtaboef, France). We assayed human IFN-a,
IRF7, TLR7, and TLR9 using Taqman Gene Expression Assay
primers with labeled probes (Applied BioSystems). Threshold cycle
(CT) values for each gene were normalized to GAPDH. The
negative control for each experiment, stimulation of pDCs with
medium alone, was assigned a value of 1, and all data are
expressed as fold induction over the negative control.
Immunofluorescence analysis
For analysis of cell surface marker expression, cells were
incubated for 15 min at room temperature in the presence of
FITC-conjugated CD80, FITC-conjugated CD83, PE-conjugated
CD40, PE-conjugated CD86, PE-Cy5-conjugated CD123, and
PE-Cy7-conjugated HLA-DR MAbs (all purchased from BD or
Beckmann Coulter). pDC apoptosis was detected using FITC-
conjugated Annexin V and 7-amino-actinomycin D (7ADD) in
Annexin V-binding buffer (Becton-Dickinson). pDCs were gated
based on size and granularity (FSC/SSC) and analyzed for the
presence of fluorescent cells. After labeling, cells were fixed in 4%
paraformaldehyde and analyzed after gating on live CD123
+/
HLA-DR
+ cells with a FACS-ARIA using DIVA software (Becton-
Dickinson, Le Pont de Claix, France). Data were analyzed by
means of Flowjo software.
Determination of IFN-a and TNF-a production by ELISA
To measure the quantities of total IFN-a and TNF-a produced,
we collected supernatants from parallel cultures after 16 to 20 h
and assayed them using a human IFN-a ELISA (PBL Laborato-
ries) or a TNF-a ELISA (Opti-EIA set, Pharmingen), respectively.
Endocytosis and endosomal maturation inhibitors
pDCs were cultured in the presence of 10
7 HCV JFH-1 per 10
5
cells per 200 ml of medium and of various endocytosis and
endosomal maturation/acidification inhibitors: dimethyl amylor-
ide (50 mM), cytochalasin D (10 mM), chlorpromazine (6.25 mg/
ml), chloroquine (5 mM), quinacrine (5 mM), NH4Cl (1 mM), and
bafilomycin A1 (50 nM), all from Sigma-Aldrich. Supernatants
were tested after 20 h for the IFN-a produced.
Statistical analysis
To compare the levels of IFN-a production by pDCs exposed to
different viruses, we used a nonparametric Mann-Whitney test. To
compare responses to TLR agonists in the presence versus absence of
HCV, we used the Wilcoxon matched pairs test. Data were analyzed
with Prism 4 Biostatistics software. All tests of significance were two-
sided, and a p value #0.05 was considered to be significant.
Supporting Information
Figure S1 Purity of viral preparations. (A) Concentrated
supernatant from Huh7.5.1 cells infected with HCV JFH-1 or
similarly concentrated supernatant from minireplicone transfected
Huh7.5.1 cells collected 16 h after UV irradiation with a 30 mJ/
cm2 dose were adsorbed onto collagen membrane-coated electron
microscopy grids. The adsorbed materials were negatively stained
with 1% uranyl acetate or with 1% sodium phosphotungstate and
observed in a Zeiss MET-EM 912 microscope. The presence of
virus-like particles of 60–80 nm in diameter in the negatively
stained viral preparation is shown by arrows. (B) Viral like particles
or exosomes are absent in supernatant from Huh7.5 cells
transfected with subgenomic (Sg) replicons. (C) We determined
the quantity and quality of RNA present in the viral preparation
using the Agilent 2100 bioanalyzer and RNA LabChipH kit.
Contamination of virus preparation with RNA material was below
the detection limits of the control methods used in our experiments
(#1 ng of RNA/ml).To determine the level of contamination of
viral preparations with cellular DNA, we also amplified by means
of GAPDH-specific PCR the DNA molecules presumably present
in 5-ml aliquots (5610
6 genome-containing virus particles) of viral
stock used to stimulate pDC cultures. No GAPDH-specific signal
was detected in 4 assayed aliquots (not shown).
Found at: doi:10.1371/journal.pone.0004319.s001 (4.53 MB
PDF)
Figure S2 Secretion of IFN-a induced with molecular clone
HCV JFH-1 and with resiquimod in pDCs from different normal
healthy donors. Cell cultures of pDCs purified from different
normal healthy donors, adjusted to a concentration of 10
6 cells/ml
in the presence of IL-3, were inoculated with 100 HCV RNA-
containing virus particles per cell or stimulated with resiquimod
(R848, 0.5 mM) in a total volume of 200 ml. Secretion of IFN-a in
cell-free supernatant was determined by means of ELISA analysis
1 day post-stimulation. Each point represents a different donor
analyzed in Figure 1.
Found at: doi:10.1371/journal.pone.0004319.s002 (0.49 MB
PDF)
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